Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pancreatic Neoplasms × Biguanides × Clear all

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Gemcitabine 182 130-nm albumin-bound paclitaxel 71 Albumin-Bound Paclitaxel 50 pembrolizumab 37 Fluorouracil 37 Leucovorin 30 Oxaliplatin 29 Capecitabine 22 Nivolumab 20 Irinotecan 17 Paclitaxel 15 Bevacizumab 15 Cetuximab 13 Erlotinib Hydrochloride 12 Cyclophosphamide 12 Taxes 11 Carboplatin 11 irinotecan sucrosofate 10 Drug Therapy 10 Injections 9 Cisplatin 9 spartalizumab 7 olaparib 6 fludarabine 6 TH 302 6 Pemetrexed 6 Docetaxel 6 ALT-803 6 avelumab 5 Ipilimumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05663515 2026-03-19

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡